Introducing our Adjuvant Systems Platform
Our next instalment of the Croda Pharma blog looks at our Adjuvant Systems platform. Keep reading to learn more about how we can support both your current and future needs for vaccine formulations.
Addressing the challenges of vaccine formulation
Your trusted adjuvant partner, today and tomorrow
With over 80 years of experience our scientists deliver high quality adjuvants to meet your vaccine formulation needs today. Beyond today we want to meet your formulation needs of the future. Our extensive expertise in immunology and formulation of adjuvant systems means we can partner with you to develop the next generation of vaccines, adapting to your requirements. We use our manufacturing experience to turn novel technologies into commercial GMP products, driven by our purpose to use ‘smart science to improve lives™’
Our adjuvant portfolio
-
PHAD™
Versatile and effective, PHAD acts as a TLR4 agonist to activate proinflammatory cytokines and antigen-specific effector cells.
-
CAF01®
Part of our new generation of adjuvants, CAF01 is a liposomal adjuvant formulation that offers excellent long-term stability and drives both humoral and cellular immune responses.
-
CAF09b®
A novel liposomal adjuvant used in cancer immunotherapy trials, CAF09b has the capacity to facilitate the production of CD8+ T-cells.
-
Adju-Phos™
Well-established as a common component in a variety of vaccines, Adju-Phos is an aluminium-based adjuvant that induces strong Th2 immune responses.
-
3D(6-acyl)-PHAD™
Immunostimulatory and highly purified, 3D(6-acyl)-PHAD activates TLR4 to induce proinflammatory cytokines and T-cells.
-
3D-PHAD™
Highly pure, safe, and chemically stable, 3D-PHAD stimulates the immune system through the activation of TLR4, leading to the production of proinflammatory cytokines, CD4+ and CD8+ T-cells.
-
Alhydrogel™
One of the most widely used vaccine adjuvants, Alhydrogel is an aluminium-based adjuvant used in clinically-approved vaccines that can elicit effective Th2 immune responses.
-
QS 21
A powerful immunostimulatory saponin that acts as a potent vaccine adjuvant, QS 21 can stimulate both cell-mediated (Th1) and humoral (Th2) immune responses
-
Quil-A™
A versatile immunostimulatory saponin that’s widely used as a potent veterinary adjuvant, Quil-A can work against both intra- and extra-cellular pathogens, stimulating innate and Th-mediated adaptive immune...
.jpg&mn=healthcare&w=768&xr=0&yr=0&xfp=6&yfp=6&hash=DFB2292D232ABFBD17192EECC1AABCEA19C138999FEC74AA)
Our adjuvant development pipeline - Cationic Adjuvant Formulation CAF®
Our adjuvant offering has expanded to offer two CAF adjuvants CAF01 and CAF09b, both showing promise for use in novel vaccines in early life and cancer immunotherapy trials respectively. If you would like to learn more about CAF or any of our other adjuvant offering contact us here.
This pipeline technology, CAF®, aims to address the weak cell mediated immunity response induced by vaccine antigens. The CAF technology platform is range of new, patented cell mediated immunity inducing cationic liposomal adjuvants.
The CAF range has a number of benefits including:
- Ensure a strong co-localisation between the antigen and adjuvant – key for inducing T-cell immunity
- Prolonged exposure of the antigen to the immune system – improving the memory profiles of the induced immunity
- Initial activation of the immune system is very localised to the injection site – reducing systemic side effects associated with vaccinations e.g. fever and system pain
If you would like to learn more about immunostimulation and where adjuvant technology is headed listen to our webinar with Dr. Dennis Christensen on demand here.
